April 15, 2011
Dear members of the bleeding disorders community,
On Sunday, alongside individuals with bleeding disorders and their families, advocates and healthcare professionals, Biogen Idec celebrates World Hemophilia Day and reinforces our strong commitment to scientific discovery focused on changing the lives of people with hemophilia.
While hemophilia is a new disease area for the company, our team isn’t new to hemophilia. We have hand selected a world-class group of scientists, clinicians, thought leaders and visionaries with extensive experience working in hemophilia. We understand how intensive hemophilia is to manage, and we are passionate about moving treatment forward.
Our aim is to dramatically shift the way hemophilia is managed worldwide by using our innovative technology to research the potential of long-lasting clotting factors. We’ve made significant progress advancing our investigational long-lasting factors for hemophilia A and B into Phase 3 clinical trials and are studying whether the products will offer fewer infusions and extended protection from bleeding.
Today, patients worldwide rely on our therapies to treat diseases like multiple sclerosis, non-Hodgkin’s lymphoma and rheumatoid arthritis, and we are dedicated to making a difference in the lives of people with hemophilia in the future. As we move ahead, we look forward to hearing from you. Your input and ideas inspire our creation of relevant and purposeful treatments, and it is only with your help that we can make much-needed progress for the hemophilia community.
For more information about our clinical programs in hemophilia, I encourage you to visit www.BiogenIdecHemophilia.com.
Glenn Pierce, MD, PhD Senior Vice President and Chief Medical Officer Biogen Idec Hemophilia
Biogen Idec Hemophilia 230 Third Avenue, 4th Floor, Waltham MA 02451 Phone 781-547-6000 www.biogenidechemophilia.com